# Xenotransplantation Transplanting organs from multiplex gene-edited pigs into humans to address the chronic shortage of donor organs, now moving from expanded-access compassionate cases into FDA-cleared clinical trials. Source: https://en.bioecon.ru/technology/xenotransplantation/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: GMO Directive 2001/18/EC & ATMP Regulation | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)] Xenotransplantation transplants living organs, tissue or cells from one species into another — specifically, from multiplex gene-edited pigs into humans — to address a chronic shortage of human donor organs that leaves dozens of patients dying on transplant waitlists every day. CRISPR-Cas9 multiplex genome editing has moved the field from research concept to clinical reality: eGenesis received FDA IND clearance for its lead candidate EGEN-2784, a genetically engineered porcine kidney, to begin a formal clinical trial for end-stage kidney disease, building on an ongoing expanded-access compassionate-use program. United Therapeutics' 10-gene-edited UHeart received FDA clearance to proceed with the EXPRESS clinical trial, a Phase 1/2/3 adaptive ("phaseless") design for pig-heart xenotransplantation. In China, Chengdu-based Zhongke Aoge Biotech has kept a gene-edited pig kidney functioning in a non-human primate recipient for more than 600 days in collaboration with Huazhong University of Science and Technology's Tongji Hospital, with all kidney-function indicators reported normal throughout. The engineering challenge these programs share is defeating several distinct rejection mechanisms at once: hyperacute rejection driven by human antibodies against pig cell-surface sugars (targeted by knocking out the GGTA1, CMAH and B4GALNT2 glycan-synthesis genes), acute vascular rejection and clotting incompatibility (addressed by adding human coagulation-regulator genes THBD and PROCR), cellular immune attack (blocked by human complement regulators CD46/CD55/CD59 and tolerance molecules HLA-E/CD47), and the biosafety risk of porcine endogenous retroviruses (PERVs), which CRISPR-Cas9 can now inactivate across all copies in the donor genome. The key directions of xenotransplantation are: 1. **Multiplex glycan knockout:** eliminating the pig-specific sugar antigens (alpha-Gal and related glycans) that trigger immediate hyperacute rejection by human antibodies. 2. **Human transgene integration:** adding human complement-regulator, coagulation-regulator and immune-tolerance genes to the pig genome so the organ is recognized as "self" by the human immune and clotting systems. 3. **PERV inactivation:** using CRISPR-Cas9 to disable every copy of the porcine endogenous retrovirus in the donor cell genome, eliminating the risk of cross-species viral transmission. 4. **Designated pathogen-free (DPF) breeding:** raising donor pigs in sealed, monitored barrier facilities to guarantee the organ is free of zoonotic pathogens at the time of transplant. ### Sectoral value chain ``` [CRISPR Design & Genome Engineering] ──> [Nuclear Transfer (SCNT)] ──> [Raising Gene-Edited Pigs] │ │ │ (Vectors, cell lines) (Embryos, surrogates) (Sterile DPF conditions) │ [Human Transplantation] <──── [Organ Procurement & Perfusion] <─────────────────────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **1. Gene editing** | Designing CRISPR cassettes, multiplex-knocking out pig glycan genes and integrating protective human transgenes into fibroblasts. | **In:** Primary pig fibroblasts, CRISPR-Cas9 systems.
**Out:** Genetically stable cell line with 10-60+ edits. | | **2. Cloning & embryo (SCNT)** | Somatic cell nuclear transfer: transplanting an edited fibroblast's nucleus into an enucleated pig oocyte to create an embryo. | **In:** Edited fibroblasts, pig oocytes.
**Out:** Reconstructed cloned embryos. | | **3. Gestation** | Transferring embryos to surrogate sows, with sterile cesarean delivery to exclude birth-canal infections. | **In:** Embryonic material, surrogate sows.
**Out:** Newborn, pathogen-free cloned piglets. | | **4. DPF rearing** | Raising the animals to 6-12 months in strictly isolated designated pathogen-free (DPF) barrier facilities with filtered air. | **In:** Newborn piglets, sterile feed, DPF enclosures.
**Out:** Healthy donor pigs free of zoonotic pathogens. | | **5. Procurement** | Explanting the kidney, heart or liver in a GMP operating room, immediate vascular flush, and connection to ex vivo perfusion. | **In:** Adult donor pig, perfusion solutions.
**Out:** Viable ex vivo organ on a life-support perfusion device. | | **6. Transplantation** | Implanting the organ in the human recipient, applying targeted immunosuppression, and lifelong PCR monitoring. | **In:** Recipient patient, prepared organ, immunosuppressants.
**Out:** Restored organ function in the recipient. | Cross-cutting technologies of the sector: - **Multiplex genome editing:** introducing dozens of genetic changes into a single cell line simultaneously, requiring high-fidelity Cas nucleases and base editors to avoid chromosomal translocations and off-target mutations. - **Designated pathogen-free (DPF) barrier technology:** closed-system pig facilities with positive air pressure, HEPA H14 filtration, effluent decontamination and autoclaved feed, with animals tested monthly against a panel of 30+ swine pathogens. - **Co-stimulation blockade immunosuppression:** next-generation monoclonal antibodies (e.g., anti-CD40/anti-CD40L agents such as tegoprubart) that selectively block T- and B-cell co-stimulatory activation pathways, preventing xenograft rejection without fully suppressing the human immune system. --- ## US The US is the undisputed global leader in translating xenotransplantation into the clinic, having performed the first-ever successful xenograft surgeries in living patients. ### FDA-cleared clinical trials, first-in-human transplants, expanded-access programs - **eGenesis:** received FDA IND clearance for EGEN-2784, its genetically engineered porcine kidney, to begin a formal clinical trial for end-stage kidney disease, building on an ongoing expanded-access compassionate-use program with reported patient updates. - **United Therapeutics / Revivicor:** its 10-gene-edited UHeart received FDA clearance to proceed with the EXPRESS clinical trial, an adaptive Phase 1/2/3 design for pig-heart xenotransplantation, following the first-ever living-patient pig-heart transplants performed under FDA expanded access. - **Miromatrix Medical (a United Therapeutics company):** its miroliverELAP, a bioengineered extracorporeal liver support device built from decellularized porcine liver matrix recellularized with human cells, received FDA RMAT (Regenerative Medicine Advanced Therapy) designation. - **Xenotherapeutics:** is running an FDA-regulated clinical trial of porcine skin xenotransplantation for complete wound closure in mixed-depth burns. --- ## CN China is rapidly closing the gap with the US, leveraging its massive animal-cloning capacity and advancing non-human primate xenotransplantation studies toward long survival benchmarks. ### large-scale pig cloning, primate survival milestones, gene-edited donor platforms - **Zhongke Aoge Biotech (Chengdu):** has kept a gene-edited pig kidney functioning in a non-human primate recipient for more than 600 days in collaboration with Huazhong University of Science and Technology's Tongji Hospital, with all kidney-function indicators reported normal — an internationally leading survival result — built on the company's integrated gene-edited pig construction and ultra-clean breeding platform. - **Cloning scale:** Chinese researchers operate automated robotic micromanipulation systems capable of cloning large numbers of gene-edited pig embryos daily, giving domestic programs a significant throughput advantage. - **Clinical translation pathway:** Chinese teams are advancing toward primate-to-clinical-trial pathways for kidney and pancreatic islet-cell xenotransplantation aimed at end-stage renal disease and type 1 diabetes. --- ## EU The EU approaches xenotransplantation with characteristic caution, prioritizing deep preclinical primate-compatibility research and strict ethical oversight over rapid clinical translation. ### primate preclinical research, ATMP regulatory framework, bioethics oversight - **LMU Munich consortium (Ludwig-Maximilians-Universität, led by Eckhard Wolf):** conducts long-term preclinical xenotransplantation research, including deep phenotyping of early human anti-porcine xenograft immune responses and studies defining which genetic modifications of source pigs are essential for successful cell, tissue and organ xenotransplantation. - **EMA regulatory posture:** treats xenogeneic organs as Advanced Therapy Medicinal Products (ATMPs), requiring exhaustive preclinical safety evidence with particular emphasis on cross-species infection risk and lifelong clinical monitoring of recipients and their close contacts. - **Ethics oversight:** active bioethics committees impose strict constraints on human trials, requiring rigorous justification at every step and minimization of donor-animal suffering. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **eGenesis** | 🇺🇸 USA | *EGEN-2784* engineered porcine kidney | Multiplex CRISPR editing, full PERV inactivation | pilot | | **Revivicor** | 🇺🇸 USA | *UHeart* / *UKidney* (10-gene pig) | FDA-cleared EXPRESS adaptive clinical trial | pilot | | **Miromatrix Medical** | 🇺🇸 USA | *miroliverELAP* bioengineered liver support | Decellularized porcine matrix + human cell recellularization | pilot | | **Xenotherapeutics** | 🇺🇸 USA | Porcine skin xenograft for burns | FDA-regulated clinical trial for burn wound closure | pilot | | **Zhongke Aoge Biotech** | 🇨🇳 China | Gene-edited pig kidney xenotransplant | 600+ day primate survival, ultra-clean breeding platform | research | | **LMU Munich** | 🇩🇪 Germany | Genetically modified donor pig research | Preclinical primate xenotransplant immunology | research | --- ## Tech stack and innovations The xenotransplantation industry relies on the following technology stack: 1. **Somatic cell nuclear transfer (SCNT):** - The only method for producing viable cloned pig offspring from deeply edited cell lines: a fibroblast nucleus carrying the edits is microinjected into an enucleated oocyte, electrofused, chemically activated, cultured to blastocyst stage, and implanted in a surrogate sow. 2. **Porcine endogenous retrovirus (PERV) inactivation:** - CRISPR-Cas9 is used to simultaneously cut and disrupt every copy of the PERV *pol* gene integrated in the donor pig genome, eliminating replication risk and making organs safe for an immunosuppressed human recipient. 3. **Normothermic ex vivo organ perfusion:** - Instead of classic ice storage (which causes ischemic tissue damage), xenografts are connected to a mobile Organ Care System that continuously circulates warm, oxygenated donor blood enriched with nutrients and anti-inflammatory hormones, minimizing vascular injury during transport. --- ## Value chains and production pipelines ### Industrial pipeline of donor pig organ production and preparation for xenotransplantation (GMP/DPF) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. CRISPR editing of pig │ ───> │ 2. Cloning (SCNT) and │ │ fibroblasts │ │ embryo transfer │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Raising pigs in │ <─── │ 3. Sterile cesarean │ │ sterile DPF zones │ │ delivery │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Organ procurement in │ ───> │ 6. Ex vivo perfusion and │ │ GMP operating room │ │ delivery to clinic │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Creating a genetically engineered pig cell line Primary fibroblasts are isolated from a newborn piglet's ear and transfected with CRISPR-Cas9 plasmids or ribonucleoprotein complexes targeting the three key pig glycan-synthesis genes (GGTA1, CMAH, B4GALNT2), while human DNA constructs carrying complement genes (CD46, CD55, CD59) and coagulation genes (THBD, PROCR) are introduced by lipofection or electroporation. Clones are selected, whole-genome sequenced to confirm all intended edits with no unwanted DNA breaks, and banked as a master cell line. #### Stage 2: Somatic cell nuclear transfer (SCNT) Oocytes are matured in vitro, enucleated under a micromanipulator, and injected with a single edited fibroblast in the perivitelline space; electrofusion and chemical activation form a reconstructed embryo, which is cultured and surgically transferred to a surrogate sow's oviduct. #### Stage 3: Sterile cesarean delivery At day 113 of gestation, the surrogate sow undergoes cesarean section under strict sterile conditions in a dedicated DPF operating suite; piglets are immediately transferred to individual sterile incubators, fully preventing transmission of birth-canal pathogens. #### Stage 4: Raising pigs in a DPF barrier module Piglets are raised on sterilized milk replacer and later autoclaved feed and purified water under continuous HEPA-filtered laminar airflow, with staff entering only through a shower airlock; blood and swabs are tested monthly by PCR for porcine cytomegalovirus, lymphotropic herpesvirus and other pathogens until the animal reaches donor-ready size (roughly 80-100 kg at 6-10 months). #### Stage 5: Donor organ procurement The prepared animal is brought to a clean GMP operating room, anesthetized, and the kidney, liver or heart is mobilized; the vasculature is flushed with an ice-cold preservation solution containing human thrombin antagonists before organ removal. #### Stage 6: Ex vivo connection, preservation and logistics The procured organ is weighed, inspected, and connected to a sterile Organ Care System perfusion device circulating modified human red blood cells, electrolytes, hormones and antibiotics at 37°C and 60-80 mmHg perfusion pressure, with continuous pH, lactate and organ blood-flow monitoring during transport (up to 12 hours) to the recipient's clinic.